Bumetanide for autism: more eye contact, less amygdala activation
Nouchine Hadjikhani(Harvard University Press), Yehezkel Ben‐Ari(Neurochlore (France)), Jakob Åsberg Johnels(University of Gothenburg), Christopher Gillberg(Sahlgrenska University Hospital), Éric Lemonnier(Laboratoire Pluridisciplinaire de Recherche en Ingénierie des Systèmes, Mécanique et Energétique), Amandine Lassalle(École Polytechnique Fédérale de Lausanne), Loyse Hippolyte(École Polytechnique Fédérale de Lausanne), Nicole R. Zürcher(Massachusetts General Hospital)
Cited by 88
Related Papers
X-Linked Mental Retardation and Autism Are Associated with a Mutation in the NLGN4 Gene, a Member of the Neuroligin Family
|The American Journal of Human Genetics|2004|762
Oxytocin-Mediated GABA Inhibition During Delivery Attenuates Autism Pathogenesis in Rodent Offspring
|Science|2014|587
Evidence for brain glial activation in chronic pain patients
|Brain|2015|499
A randomised controlled trial of bumetanide in the treatment of autism in children
|Translational Psychiatry|2012|310
Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders
|Translational Psychiatry|2017|210